{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000060","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.108136+00:00","generated_at":"2026-06-03T02:27:24.308866+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent Q1 rev $300M, net income $9M; raises FY2024 adj EBITDA guidance to $125-175M","bullets":["Q1 2024 total revenues $300.4M (up 83% YoY), net income $9.0M vs loss of $186.2M last year.","Adjusted EBITDA $66.9M vs $(101.5)M; adjusted EPS $0.59 vs $(3.26).","FY2024 guidance raised: total rev $1.0-1.1B, adj EBITDA $125-175M, adj net loss $(65)-(15)M.","ASPR contract modification reduces minimum purchase from 9M to 3.5M doses annually for Option Years 5-9; max contract value revised to $1.4B.","NARCAN sales up 18% to $118.5M; MCM segment gross margin improved to 60%."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000060","json":"https://secwatch.observer/filing/0001367644-24-000060.json","markdown":"https://secwatch.observer/filing/0001367644-24-000060.md","text":"https://secwatch.observer/filing/0001367644-24-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000060/0001367644-24-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000060/ebs-20240429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:27:24.308866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}